Inherited or Acquired in Hipertension and Cronic Kidney Disease in Diabetes Mellitus Patients?

1. Van Gelder VA,Scherpbier-de Haan ND, de Graw WJ, O Callaghan CA, Wetzels JF, Lasserson DS.Impact on cardiovascular risk follow-up from a shift to the CKD-EPI formula for eGFR reporting: a cross-selectional population-based primary care study.BMJ Open.2013;3(9):e00363110.1136/bmjopen-2013-003631 Search in Google Scholar

2. Wong MG, Pollock CA, Cooper BA, Branley P, Collins JF, Criag JC, Kesselhut J, Luxton G,Pilmore A, Harris DC,Johnson DW. Association between GFR estimated by multiple methods at dialysis commencement and patient survival.Clin J Am Soc Nephrol. 2013;Oct 3110.2215/CJN.02310213 Search in Google Scholar

3. Pagano E,Bo S, Petrico M, Rosato R,Merletti F, GregoriD.Factors affecting hospitalization costs in type 2 diabetic patients. J Diabetes Complications.2009;23:1-610.1016/j.jdiacomp.2007.09.006 Search in Google Scholar

4. Tang SC, Chan GC, Lai KN. Recent advances in managing and understanding diabetic nephropathy. F1000Res.2016.510.12688/f1000research.7693.1 Search in Google Scholar

5. Mogensen CE.Definition of diabeticrenal disease in insulin dependent diabetes mellitus,based on renal function tests.In:The Kidney and Hypertension in Diabetes Mellitus, Mogensen Ce (ed),Kluwer Academic Publishers, Boston, USA.2000;13-29.10.1007/978-1-4615-4499-9_2 Search in Google Scholar

6. KDIGO.KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Supplements.2013;3:15-18 Search in Google Scholar

7. Eknoyan G, Hostetter T,Bakris GL, Hebert L, Levey AS, Parving HH, Steffes Mw,Toto R.Proteinuria and other markers of chronic kidney disase:a position statement of yhe National Kidney Foundation (NKF) and the National Institute of Diabetes and Digestive and Kidney Diseases(NIDDK).Am J Kidney Dis.2003;42:617-622.10.1016/S0272-6386(03)00826-6 Search in Google Scholar

8. American Diabetes Association. Clinical Practice Recommendations 2000; 23(Suppl) Search in Google Scholar

9. Parving H,Osterby R,Anderson P et al. Diabetic nephropathy. In : Brenner B, ed.The Kidney. WB Saunders Co, Philadelphia, 1996;1874-1875 Search in Google Scholar

10. Smith SR, Svetkey LP, DennisVW.Racial differences in the incidence and progression of renal diseases. Kidney Int.1991; 40:815-82210.1038/ki.1991.281 Search in Google Scholar

11. Cimponeriu D, Craciun AM, Apostol P, Radu I, Guja C, Cheta D, The genetic background of diabetes chronic complications.In : Genetics of diabetes. The Thrth Unveiled. Cheta D (ed. ED Acad Rom &S, Karger AG, Bucharest/Basel.2001;193-334. Search in Google Scholar

12. Freedman B. I., Bostrom M., Daeihagh P., Bowden D. W. Genetic factors in diabetic nephropathy. 2007;2(6):1306–1316. Search in Google Scholar

13. Bretzel RG.Effects of antihypertensive drugs on renal function in patients with diabetic nephropathy.Am.J Hypertens, 10:208S-217S,1997.10.1016/S0895-7061(97)00155-6 Search in Google Scholar

14. Roglic G,Cohoun HM,Stevens LK,Lemkes HH,Manes C,Fuller JH.Parenteral history of hypertension and parental history of diabetes and microvascular complications in insulin-dependent diabetes mellitus:the EURODIAB IDDM Complications Study.Diabet Med,15:418-426,1998. Search in Google Scholar

15. De Cosmo S, Bacci S, Piras GP, Cignarelli M,Placentino G,Margaglione M, Colaizzzo D, Di Minno G, Giorgino R, Liuzzi A,Viberti GC.High prevalence of risk factors for cardiovascular disease in parents of IDDM patients with albuminuria.Diabetologia,40:1191-1196,1997.10.1007/s0012500508069349601 Search in Google Scholar

16. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR; UKPDS Study Group: Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006;55: 1832–1839.10.2337/db05-162016731850 Search in Google Scholar

17. Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM; RENAAL Study Group: Effects of blood pressure level on progression of diabetic nephropathy: Results from the RENAAL study. Arch Intern Med 2003;163: 1555–1565.10.1001/archinte.163.13.1555 Search in Google Scholar

18. 24. Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, Esmatjes E, Gilbert RE, Hunsicker LG, de Faria JB, Mangili R, Moore J Jr., Reisin E, Ritz E, Schernthaner G, Spitalewitz S, Tindall H, Rodby RA, Lewis EJ: Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: Clinical implications and limitations. J Am Soc Nephrol 2005;16: 3027–3037.10.1681/ASN.2004110919 Search in Google Scholar

19. Ayaeha A, Motala MD. Management of hypertension in diabetes mellitus. JIMSA 1997; 3:1-9 Search in Google Scholar

20. Lewis Ej, Hunsicher LG,Clarke WR, et al. Renoprotective effect of angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.N Engl J Med.2001;345:851-860.10.1056/NEJMoa011303 Search in Google Scholar

21. Brenner BM, Cooper ME, de Zeeuw D, ey al. Effects of losartan on renal and cardiovascular outcomes in patienys with type 2 diabetes and nephropathy. N Engl J Med .2001;345:861-869.10.1056/NEJMoa011161 Search in Google Scholar

22. Mauer M, Zinman B, Gardiner R, et al.Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med .2009;361:40-51.10.1056/NEJMoa0808400 Search in Google Scholar

23. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O’Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P; VA NEPHRON-D Investigators: Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369: 1892–1903.10.1056/NEJMoa1303154 Search in Google Scholar

24. Unger T. The role of renin-angiotensin system in the development of cardiovascular disease.Am J Cardiol.2002;89(Suppla):3A-10.10.1016/S0002-9149(01)02321-9 Search in Google Scholar

25. Agarwal A, Williams GH,Fisher ND.Genetics of human hypertension.Trends Endocrinol Metab, 16:127-133,2005.10.1016/j.tem.2005.02.00915808811 Search in Google Scholar

26. SPRINT Research Group, Wright JT Jr., Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr., Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT: A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373: 2103–2116.10.1056/NEJMoa1511939468959126551272 Search in Google Scholar

27. Churchill PC,Churchill MC, Bidari AK et al.Genetic susceptibility to hypertension induced renal damage in the rat.J Clin Invest 1997; 100:1373-138210.1172/JCI1196575083159294102 Search in Google Scholar

28. Toto R.Hypertension in the failing kidney. Curr Opin Nephrol Hypertens 2001; 10:165-16610.1097/00041552-200103000-0000211224689 Search in Google Scholar

29. Krolewski A.Genetic susceptibility to diabetic nephropathy.Kidney Int 1999; 55:1582-159610.1046/j.1523-1755.1999.00371.x10201028 Search in Google Scholar

30. Demaine AG, Heesom AE,Cross D et al.Investigation of polymorphisms of aldose reductase promoter region in patients with type 1 diabetes and diabetic microvascular complications. Abstract of 60^th Scientific Sessions of the American Diabetes Association, San Antonio, Texas, 2000; Abstract 76-OR Search in Google Scholar

31. World Health Statistics World Health Statistics. Geneva: Global report on diabetes; (2016). Search in Google Scholar